JPMorgan Chase & Co. Raises Septerna (NASDAQ:SEPN) Price Target to $38.00

Septerna (NASDAQ:SEPN) had its target price increased by analysts at JPMorgan Chase & Co. from $34.00 to $38.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 56.96% from the stock’s current price.

A number of other analysts also recently commented on the company. Wall Street Zen downgraded Septerna from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Cantor Fitzgerald restated an “overweight” rating and issued a $60.00 target price on shares of Septerna in a research note on Tuesday, March 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research report on Thursday, January 22nd. JonesTrading began coverage on shares of Septerna in a research note on Tuesday, December 23rd. They set a “buy” rating and a $43.00 price target on the stock. Finally, HC Wainwright boosted their price target on shares of Septerna from $35.00 to $40.00 and gave the company a “buy” rating in a report on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Septerna has a consensus rating of “Moderate Buy” and an average price target of $43.14.

Septerna Stock Performance

Shares of SEPN opened at $24.21 on Tuesday. The company has a 50-day simple moving average of $26.51 and a 200-day simple moving average of $24.09. The firm has a market capitalization of $1.09 billion, a P/E ratio of -21.81 and a beta of 3.46. Septerna has a 52 week low of $4.66 and a 52 week high of $32.63.

Septerna (NASDAQ:SEPN) last released its earnings results on Monday, March 9th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). Septerna had a negative return on equity of 15.85% and a negative net margin of 106.37%.The firm had revenue of $24.12 million for the quarter, compared to analyst estimates of $20.44 million. As a group, equities analysts forecast that Septerna will post -7.11 earnings per share for the current year.

Insider Buying and Selling

In other Septerna news, COO Elizabeth Bhatt sold 4,000 shares of Septerna stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $28.97, for a total transaction of $115,880.00. Following the sale, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at approximately $5,046,834.73. The trade was a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Samira Shaikhly sold 70,453 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $28.10, for a total value of $1,979,729.30. Following the completion of the transaction, the insider directly owned 793 shares of the company’s stock, valued at approximately $22,283.30. The trade was a 98.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 4.30% of the stock is currently owned by insiders.

Institutional Trading of Septerna

A number of large investors have recently bought and sold shares of SEPN. Goldman Sachs Group Inc. lifted its holdings in shares of Septerna by 86.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock valued at $75,698,000 after acquiring an additional 1,260,409 shares during the period. First Light Asset Management LLC bought a new stake in shares of Septerna in the 4th quarter worth about $17,308,000. Primecap Management Co. CA bought a new stake in shares of Septerna in the 4th quarter worth about $15,225,000. Perceptive Advisors LLC acquired a new stake in shares of Septerna during the 2nd quarter worth about $5,723,000. Finally, VR Adviser LLC acquired a new stake in shares of Septerna during the 2nd quarter worth about $5,713,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.